Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

Author： Karnon Jonathan  

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.9, Iss.2, 2008-05, pp. : 171-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer

By Lipsitz Michael   Delea Thomas E.   Guo Amy  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2315-2328

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

By  

Oncology Research and Treatment, Vol. 33, Iss. 4, 2010-03 ,pp. : 155-166

Karger

Access to resources Recommend Favorite

The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial

By  

Oncology, Vol. 81, Iss. 5-6, 2011-12 ,pp. : 298-305

Karger

Access to resources Recommend Favorite

Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer

By Grant Margaret   Rea Daniel W  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 305-318

Future Medicine

Access to resources Recommend Favorite

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer

By Ligibel Jennifer A   Winer Eric P  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 89-97

Future Medicine

Access to resources Recommend Favorite